ARTICLE | Finance
Ebb & Flow
February 25, 2002 8:00 AM UTC
Six of the seven companies that discussed partnerships for ImClone's Erbitux anti-EGFR antibody said they will comply with last week's requests from the House Energy and Commerce Committee for "all records including internal audits, investigations, and/or reports relating to ImClone Systems." (see BioCentury Extra, Thursday Feb. 25).
Amgen (AMGN), Chiron (CHIR), Eli Lilly (LLY), Johnson & Johnson (JNJ), Merck (MRK) and Pharmacia (PHA) all told Ebb & Flow that they will cooperate with the committee. The seventh company, Abbott (ABT), said it is reviewing the letter. ...